2394-25-4

Basic information

• Product Name: 17-Deoxy Cortienic Acid
• Synonyms: 17-Deoxy Cortienic Acid
• CAS NO: 2394-25-4
• Molecular Formula: C₂₀H₂₈O₄
• Molecular Weight: 332.43392
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals, Steroids
• Mol File: 2394-25-4.mol

Chemical Properties

• Melting Point: 253-255 °C
• Boiling Point: 527.0±50.0 °C(Predicted)
• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Acetonitrile (Slightly, Heated), Chloroform (Slightly, Heated), DMSO (Slightly),
• PKA: 4.71±0.70(Predicted)
• CAS DataBase Reference: 17-Deoxy Cortienic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 17-Deoxy Cortienic Acid(2394-25-4)
• EPA Substance Registry System: 17-Deoxy Cortienic Acid(2394-25-4)

Safety Data

• Hazardous Substances Data: 2394-25-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
17-Deoxy Cortienic Acid is used as a key intermediate in the synthetic preparation of macrolactonolides, a class of potential anti-inflammatory drugs. These macrolactonolides have shown promise in treating various inflammation-related conditions due to their ability to modulate the immune response and reduce inflammation.
In the development of anti-inflammatory drugs, 17-Deoxy Cortienic Acid serves as a crucial building block, enabling the creation of novel compounds with enhanced efficacy and reduced side effects. Its role in the synthesis process highlights its importance in advancing pharmaceutical research and drug development.
Additionally, given its potential applications in other areas, further research and development may reveal new uses for 17-Deoxy Cortienic Acid in various industries, such as cosmetics, agriculture, or materials science. However, based on the provided materials, its primary application is in the pharmaceutical industry for the development of anti-inflammatory drugs.

Upstream product

• 50-22-6 Corticosterone 
• 110247-37-5 11β-hydroxy-3-oxo-5β-androstane-17β-carboxylic acid 
• 64-17-5 ethanol 
• 7664-93-9 sulfuric acid 
• 50-23-7 HYDROCORTISONE 
• 10486-85-8 (8S,9S,10R,11S,13S,14S,17S)-methyl 11-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8, 9,10,11,12,13, 14, 15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-carboxylate 

Relevant articles and documents

17-KETOSTEROIDS VIA A BASE INDUCED CLEAVAGE OF C-17-DIHYDROXY ACETONE SIDE CHAINS

A new, base-catalyzed cleavage of C21-steroids to give 17-ketosteroids is described.This reaction is specific for those steroids containing the C-17-dihydroxy acetone side chain.In the presence of oxygen, these same reaction conditions readily degrade corticosterone to the 17β-carboxylic acid.

HYDROXYSTEROID COMPOUNDS, THEIR INTERMEDIATES, PROCESS OF PREPARATION, COMPOSITION AND USES THEREOF

The present invention relates to novel steroidal compounds of formula (I), process for preparation of the same and composition comprising these compounds.

Raw synthesis and mitochondrial function postischemic mitochondria diseases related to the lack or for use in new compd. 11β-hydroxysteroid

The present invention provides novel compounds of 112-hydroxy steroids and compositions and their application as pharmaceuticals for preventing or reversing injury to mitochondria, for treating or preventing diseases relating to mitochondrial dysfunction or depletion, and for inducing regeneration or restructuring of mitochondria as a means of treating diseases relating to abnormalities in mitochondrial structure and function in a human or animal subject. Also disclosed herein are methods for diagnosing injury to mitochondria and for diagnosing the success or failure of therapeutics designed to treat, prevent, or reverse injury to or depletion of mitochondria.

Macrolactonolides: A novel class of anti-inflammatory compounds

A new concept in design of safe glucocorticoid therapy was introduced by conjugating potent glucocorticoid steroids with macrolides (macrolactonolides). These compounds were synthesized from various steroid 17β-carboxylic acids and 9a-N-(3-aminoalkyl) derivatives of 9-deokso-9a-aza-9a-homoeritromicin A and 3-descladinosyl-9-deokso-9a-aza-9a-homoeritromicin A using stable alkyl chain. Combining property of macrolides to preferentially accumulate in immune cells, especially in phagocyte cells, with anti-inflammatory activity of classic steroids, we designed molecules which showed good anti-inflammatory activity in ovalbumin (OVA) induced asthma in rats. The synthesis, in vitro and in vivo anti-inflammatory activity of this novel class of compounds are described.